Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China

Abstract Background Dasatinib and imatinib are the recommended tyrosine kinase inhibitors (TKIs) for treating pediatric Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), and the one which has been approved indication in China is imatinib. Recently, clinical demand for Ph + ALL treatment...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wang Cao, Yuncui Yu, Yingpeng Qiu, Lu Liu, Hao Zhang, Liwei Shi, Yue Xiao, Lulu Jia, Ruidong Zhang, Xiaoling Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-12-01
coleção:	BMC Health Services Research
Assuntos:	Philadelphia-positive acute lymphoblastic leukemia Dasatinib Imatinib Cost-effectiveness analysis Children
Acesso em linha:	https://doi.org/10.1186/s12913-022-08971-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!